Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Moderna (MRNA) closed the latest trading ... Prior to today's trading, shares of the biotechnology company had gained 3.19% over the past month. This has outpaced the Medical sector's gain of ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

The primary endpoint of the trial is disease-free survival (DFS) with an overall follow-up period of up to 78 months ... its worth in the COVID-19 pandemic. Moderna’s arch-rival in the mRNA ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The high-speed train service between Paris and Milan will resume operations in March and April, after a 19-month closure due to a landslide. The restored route will once again connect travelers ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...

Moderna's MRNA +3.99% Get Free Report short percent of float has risen 13.6% since its last report. The company recently ...